Dokument: Psychoonkologische Belastung, Risikofaktoren und Betreuungsbedarf von Patienten mit niedriggradigen Hirntumoren
| Titel: | Psychoonkologische Belastung, Risikofaktoren und Betreuungsbedarf von Patienten mit niedriggradigen Hirntumoren | |||||||
| Weiterer Titel: | Psychooncological distress, risk factors and treatment demand in patients with low-grade glioma | |||||||
| URL für Lesezeichen: | https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=69681 | |||||||
| URN (NBN): | urn:nbn:de:hbz:061-20250526-082327-4 | |||||||
| Kollektion: | Dissertationen | |||||||
| Sprache: | Deutsch | |||||||
| Dokumententyp: | Wissenschaftliche Abschlussarbeiten » Dissertation | |||||||
| Medientyp: | Text | |||||||
| Autor: | Pfab, Alessandra [Autor] | |||||||
| Dateien: |
| |||||||
| Beitragende: | PD Dr. med. Rapp, Marion [Gutachter] Niccolai, Valentina [Gutachter] | |||||||
| Stichwörter: | low-grade glioma, distress, HADS, Po-Bado, DT | |||||||
| Dewey Dezimal-Klassifikation: | 600 Technik, Medizin, angewandte Wissenschaften » 610 Medizin und Gesundheit | |||||||
| Beschreibungen: | Patienten mit niedriggradigen Hirntumoren (LGG) leben mit dem ständigen Wissen der Unheilbarkeit ihrer Erkrankung und der Gewissheit einer Malignisierung im Verlauf. Da LGG vor allem junge Patienten betrifft, welche mitten im Berufs- und Familienleben stehen, stellt die Diagnose durch plötzliche Einschränkungen im Alltag ein einschneidendes Ereignis dar. Es ist bekannt, dass dies zu Distress und Depression führen kann und damit mit einer verminderten Lebensqualität (HRQoL) und einer kürzeren Überlebenszeit einhergeht. Nichtsdestotrotz fehlen standardisierte Screeningverfahren zur Erfassung von Distress und krankheitsspezifische Risikofaktoren für psychische Belastung sind weitestgehend unerforscht.
Diese Studie wurde durchgeführt, um Auftreten und Risikofaktoren für Distress bei LGG zu analysieren sowie vorhandene Screeningverfahren miteinander zu vergleichen mit dem Ziel, ein geeignetes Verfahren zur Detektion von Belastung und psychoonkologischem Betreuungsbedarf in dieser Patientengruppe zu finden. Hierzu wurden Patienten mit gesichertem LGG sowie dem bildmorphologischen Verdacht auf ein LGG mittels drei Selbsteinschätzungsfragebögen (Hospital Anxiety and Depression Scale, Distress Thermometer, EORTC -QLQ-C30/BN20) sowie einem Fremdeinschätzungsbogen (Psychoonkologische Basisdokumentation) untersucht und die Ergebnisse mit soziodemografischen Faktoren korreliert. 149 Patienten wurden in die Studie eingeschlossen und in unterschiedliche Subgruppen bezüglich des Screeningzeitpunktes und der Diagnose eingeteilt. Erhöhte Belastung konnte bei 22.1% der Patienten nachgewiesen werden. Signifikant mit Belastung assoziierte Faktoren waren präexistente psychiatrische Vorerkrankungen und Vorbehandlungen. Bei Patienten ohne gesicherte histopathologische Diagnose konnte eine höhere Lebensqualität sowie globaler Gesundheitsstand und eine höhere Zukunftsunsicherheit beobachtet werden. Die Subgruppenanalyse des EORTC-QLQ-C30/BN20 zeigen eine signifikante Korrelation mit erhöhten Distress und scheinen damit zur Abbildung und Screening dessen geeignet. Weitere, hier nicht einbezogene Elemente sollten jedoch im Verlauf weiter auf ihre Eignung untersucht werden. Die Studienergebnisse unterstreichen die Notwendigkeit eines regelmäßigen Screenings auf Distress und die Unverzichtbarkeit des Angebots einer psychoonkologischen Unterstützung für Patienten mit LGG unter besonderer Beachtung der Patienten mit vorhandenen Risikofaktoren.Patients diagnosed with a low- grade glioma (LGG) must live with the constant knowledge of the incurability of their disease and upcoming malignant tumor transformation. As LGG appear mostly in younger patients who are in the middle of their family and working life, the diagnosis represents a sudden restriction which may lead to increased anxiety and reduced health related quality of life (HRQoL). It is known that this can lead to a decreased quality of life and survival time. However, standardized screening methods to portray and detect distress are missing and disease-specific risk factors for mental distress are yet uninvestigated. This study aims to analyse the occurrence and risk factors for distress in patients with LGG using different screening tools to subsequently evaluate their need for psychological support and prevalence of distress. Patients with LGG-suspicious findings in MRI studies as well as patients with histopathological confirmed LGG were screened using three established self-assessment instruments (Hospital Anxiety and Depression Scale, Distress Thermometer, EORTC-QLQ-C30/BN20) as well as one external assessment (Basic documentation for Psycho-Oncology). Screening results were correlated with sociodemographic factors. 149 patients were prospectively included. Patients were further divided into different subgroups regarding the time of screening and diagnosis. An increased level of distress was observed in 22.1 % of all screened patients. Significant associated factors were pre-existing psychiatric disorders and psychotropic premedication. HRQoL and global health as well as future uncertainty assessed by the EORTC-QLQ-C30/BN2 were significantly higher in those patients without histopathological diagnosis. Increased distress was significantly correlated with results in chosen subitems of the HRQoL questionnaire. These items seem to be suited to detect distress, further elements that were excluded in this study should nevertheless be further evaluated concerning their suitability for screening. These screening results highlight the necessity for a suitable screening method and frequent screening for distress and furthermore the indispensability to offer psychooncological support to LGG patients. Patients with known risk factors should be paid special attention to. | |||||||
| Quelle: | 1. Louis, D.N., et al., The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol, 2016. 131(6): p. 803-20.
2. Kahlenberg, C.A., et al., Seizure prognosis of patients with low-grade tumors. Seizure, 2012. 21(7): p. 540-5. 3. Sanai, N., S. Chang, and M.S. Berger, Low-grade gliomas in adults. J Neurosurg, 2011. 115(5): p. 948-65. 4. Pouratian, N., et al., Surgery Insight: the role of surgery in the management of low-grade gliomas. Nat Clin Pract Neurol, 2007. 3(11): p. 628-39. 5. Claus, E.B. and P.M. Black, Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973-2001. Cancer, 2006. 106(6): p. 1358-63. 6. Schlegel, U., Neue WHO-Klassifikation der Hirntumore. Im Focus Onkologie, (2017). 7. Affronti, M.L., et al., Pilot Study to Describe the Trajectory of Symptoms and Adaptive Strategies of Adults Living with Low-grade Glioma. Semin Oncol Nurs, 2018. 34(5): p. 472-485. 8. Dolecek, T.A., et al., CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol, 2012. 14 Suppl 5: p. v1-49. 9. W., W.W.e.a.W. Gliome, S2k-Leitlinie, 2021, in: Deutsche Gesellschaft für Neurologie (Hrsg.), . 2021 [cited 2022 06.01.2022]. 10. Forst, D.A., et al., Low-grade gliomas. Oncologist, 2014. 19(4): p. 403-13. 11. Louis, D.N., et al., The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol, 2021. 23(8): p. 1231-1251. 12. Ostrom, Q.T., et al., CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol, 2015. 17 Suppl 4: p. iv1-iv62. 13. Hartmann, C., et al., Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol, 2010. 120(6): p. 707-18. 14. Leeper, H.E., et al., IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Oncotarget, 2015. 6(30): p. 30295-305. 15. Weller, M., et al., EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol, 2021. 18(3): p. 170-186. 16. Bady, P., M. Delorenzi, and M.E. Hegi, Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors. J Mol Diagn, 2016. 18(3): p. 350-361. 17. Pamir, M.N., et al., First intraoperative, shared-resource, ultrahigh-field 3-Tesla magnetic resonance imaging system and its application in low-grade glioma resection. J Neurosurg, 2010. 112(1): p. 57-69. 18. Smits, M., Imaging of oligodendroglioma. Br J Radiol, 2016. 89(1060): p. 20150857. 19. van den Bent, M.J., et al., Diffuse Infiltrating Oligodendroglioma and Astrocytoma. J Clin Oncol, 2017. 35(21): p. 2394-2401. 20. Ginsberg, L.E., et al., The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol, 1998. 49(4): p. 436-40. 21. Morita, N., et al., Dynamic susceptibility contrast perfusion weighted imaging in grading of nonenhancing astrocytomas. J Magn Reson Imaging, 2010. 32(4): p. 803-8. 22. Rapp, M., et al., Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med, 2013. 54(2): p. 229-35. 23. Jansen, N.L., et al., MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging, 2012. 39(6): p. 1021-9. 24. Rees, J., et al., Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation. Eur J Radiol, 2009. 72(1): p. 54-64. 25. Wilden, J.A., et al., Strategies to maximize resection of complex, or high surgical risk, low-grade gliomas. Neurosurg Focus, 2013. 34(2): p. E5. 26. Eigenbrod, S., et al., Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients. Acta Neurochir (Wien), 2014. 156(8): p. 1427-40. 27. Stummer, W., et al., Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol, 2006. 7(5): p. 392-401. 28. De Witt Hamer, P.C., et al., Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol, 2012. 30(20): p. 2559-65. 29. Mandonnet, E., et al., Initial experience using awake surgery for glioma: oncological, functional, and employment outcomes in a consecutive series of 25 cases. Neurosurgery, 2015. 76(4): p. 382-9; discussion 389. 30. Jakola, A.S., et al., Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA, 2012. 308(18): p. 1881-8. 31. Kamp, M.A., et al., Is it all a matter of size? Impact of maximization of surgical resection in cerebral tumors. Neurosurg Rev, 2019. 42(4): p. 835-842. 32. Capelle, L., et al., Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article. J Neurosurg, 2013. 118(6): p. 1157-68. 33. Duffau, H., Resecting diffuse low-grade gliomas to the boundaries of brain functions: a new concept in surgical neuro-oncology. Journal of Neurosurgical Sciences, 2015. 59(4): p. 361-371. 34. Cairncross, J.G. and N.J. Laperriere, Low-grade glioma. To treat or not to treat? Arch Neurol, 1989. 46(11): p. 1238-9. 35. Duffau, H. and L. Taillandier, New concepts in the management of diffuse low-grade glioma: Proposal of a multistage and individualized therapeutic approach. Neuro Oncol, 2015. 17(3): p. 332-42. 36. Brar, K., et al., Management of Diffuse Low-Grade Glioma: The Renaissance of Robust Evidence. Front Oncol, 2020. 10: p. 575658. 37. Jakola, A.S., et al., Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol, 2017. 28(8): p. 1942-1948. 38. Duffau, H., Paradoxes of evidence-based medicine in lower-grade glioma: To treat the tumor or the patient? Neurology, 2018. 91(14): p. 657-662. 39. Jakola, A.S., et al., Surgical strategy in grade II astrocytoma: a population-based analysis of survival and morbidity with a strategy of early resection as compared to watchful waiting. Acta Neurochir (Wien), 2013. 155(12): p. 2227-35. 40. Buckner, J.C., et al., Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med, 2016. 374(14): p. 1344-55. 41. Bell, E.H., et al., Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. J Clin Oncol, 2020. 38(29): p. 3407-3417. 42. Kaloshi, G., et al., Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology, 2007. 68(21): p. 1831-6. 43. Niyazi, M., et al., ESTRO-ACROP guideline "target delineation of glioblastomas". Radiother Oncol, 2016. 118(1): p. 35-42. 44. van den Bent, M.J., et al., Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet, 2005. 366(9490): p. 985-90. 45. Shaw, E.G., et al., Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol, 2012. 30(25): p. 3065-70. 46. Stupp, R., et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 2005. 352(10): p. 987-96. 47. Weller, M. and E. Le Rhun, How did lomustine become standard of care in recurrent glioblastoma? Cancer Treat Rev, 2020. 87: p. 102029. 48. Riba, M.B., et al., Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2019. 17(10): p. 1229-1249. 49. Carlson, L.E., et al., High levels of untreated distress and fatigue in cancer patients. Br J Cancer, 2004. 90(12): p. 2297-304. 50. Keir, S.T., et al., Stress and intervention preferences of patients with brain tumors. Support Care Cancer, 2006. 14(12): p. 1213-9. 51. Giovagnoli, A.R., et al., Facets and determinants of quality of life in patients with recurrent high grade glioma. J Neurol Neurosurg Psychiatry, 2005. 76(4): p. 562-8. 52. Pelletier, G., et al., Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 2002. 57(1): p. 41-9. 53. Skarstein, J., et al., Anxiety and depression in cancer patients: relation between the Hospital Anxiety and Depression Scale and the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire. J Psychosom Res, 2000. 49(1): p. 27-34. 54. Litofsky, N.S. and A.G. Resnick, The relationships between depression and brain tumors. J Neurooncol, 2009. 94(2): p. 153-61. 55. Pringle, A.M., R. Taylor, and I.R. Whittle, Anxiety and depression in patients with an intracranial neoplasm before and after tumour surgery. Br J Neurosurg, 1999. 13(1): p. 46-51. 56. Wellisch, D.K., et al., Predicting major depression in brain tumor patients. Psychooncology, 2002. 11(3): p. 230-8. 57. Mainio, A., et al., Depression in relation to anxiety, obsessionality and phobia among neurosurgical patients with a primary brain tumor: a 1-year follow-up study. Clin Neurol Neurosurg, 2011. 113(8): p. 649-53. 58. Schwenk, T.L., Cancer and depression. Prim Care, 1998. 25(2): p. 505-13. 59. Kost, C., et al., [Change in psychological distress of cancer in-patients attending a structured psychooncological care program]. Psychother Psychosom Med Psychol, 2009. 59(12): p. 432-9. 60. Litofsky, N.S., et al., Depression in patients with high-grade glioma: results of the Glioma Outcomes Project. Neurosurgery, 2004. 54(2): p. 358-66; discussion 366-7. 61. Mainio, A., et al., Depression in relation to survival among neurosurgical patients with a primary brain tumor: a 5-year follow-up study. Neurosurgery, 2005. 56(6): p. 1234-41; discussion 1241-2. 62. Mainio, A., et al., Decreased quality of life and depression as predictors for shorter survival among patients with low-grade gliomas: a follow-up from 1990 to 2003. Eur Arch Psychiatry Clin Neurosci, 2006. 256(8): p. 516-21. 63. Parker, P.A., et al., Psychosocial and demographic predictors of quality of life in a large sample of cancer patients. Psychooncology, 2003. 12(2): p. 183-93. 64. Goebel, S. and H.M. Mehdorn, Measurement of psychological distress in patients with intracranial tumours: the NCCN distress thermometer. J Neurooncol, 2011. 104(1): p. 357-64. 65. Blagden, S.P., et al., Performance status score: do patients and their oncologists agree? Br J Cancer, 2003. 89(6): p. 1022-7. 66. Mainio, A., et al., Depression and functional outcome in patients with brain tumors: a population-based 1-year follow-up study. J Neurosurg, 2005. 103(5): p. 841-7. 67. Kvale, E.A., et al., Distress and quality of life in primary high-grade brain tumor patients. Support Care Cancer, 2009. 17(7): p. 793-9. 68. Rooney, A.G., A. Carson, and R. Grant, Depression in cerebral glioma patients: a systematic review of observational studies. J Natl Cancer Inst, 2011. 103(1): p. 61-76. 69. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., AWMF): Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatienten, Langversion 1.1. AWMF-Registernummer: 032/051OL 2014. 70. Mitchell, A.J., et al., Acceptability of common screening methods used to detect distress and related mood disorders-preferences of cancer specialists and non-specialists. Psychooncology, 2008. 17(3): p. 226-36. 71. Duffau, H., Diffuse low-grade glioma, oncological outcome and quality of life: a surgical perspective. Curr Opin Oncol, 2018. 30(6): p. 383-389. 72. Hickmann, A.K., et al., Evaluating patients for psychosocial distress and supportive care needs based on health-related quality of life in primary brain tumors: a prospective multicenter analysis of patients with gliomas in an outpatient setting. J Neurooncol, 2017. 131(1): p. 135-151. 73. Wang, G.L., et al., The HADS and the DT for screening psychosocial distress of cancer patients in Taiwan. Psychooncology, 2011. 20(6): p. 639-46. 74. Graves, K.D., et al., Distress screening in a multidisciplinary lung cancer clinic: prevalence and predictors of clinically significant distress. Lung Cancer, 2007. 55(2): p. 215-24. 75. Carroll, B.T., et al., Screening for depression and anxiety in cancer patients using the Hospital Anxiety and Depression Scale. Gen Hosp Psychiatry, 1993. 15(2): p. 69-74. 76. Osborne, R.H., et al., The value of the Hospital Anxiety and Depression Scale (HADS) for comparing women with early onset breast cancer with population-based reference women. Qual Life Res, 2004. 13(1): p. 191-206. 77. Ransom, S., P.B. Jacobsen, and M. Booth-Jones, Validation of the Distress Thermometer with bone marrow transplant patients. Psychooncology, 2006. 15(7): p. 604-12. 78. Netw., J.N.C.C., National Comprehensive Cancer N. Distress management. Clinical practice guidelines. . 2003;: p. 1(3):344-374. 79. Rapp, M., et al., Impact of distress screening algorithm for psycho-oncological needs in neurosurgical patients. Oncotarget, 2018. 9(60): p. 31650-31663. 80. Mirjam Renovanz - Universitätsklinikum Tübingen, T., Deutschland, et al., Holistic needs assessment in brain tumour patients – optimisation of the Distress Thermometer in Germany (HEAT-study) Bedarfserfassung optimieren – die Adaptation des Belastungsthermometers für Hirntumorpatienten in Deutschland (HEAT-Studie). 2020. p. doi: 10.3205/20dgnc128, urn:nbn:de:0183-20dgnc1280, Veröffentlicht: 26. Juni 2020. 81. Roth, A.J., et al., Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer, 1998. 82(10): p. 1904-8. 82. Aaronson, N.K., et al., The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst, 1993. 85(5): p. 365-76. 83. Sprangers, M.A., et al., The European Organization for Research and Treatment of Cancer. Approach to quality of life assessment: guidelines for developing questionnaire modules. EORTC Study Group on Quality of Life. Qual Life Res, 1993. 2(4): p. 287-95. 84. Fayers, P., et al., Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur J Cancer, 2002. 38 Suppl 4: p. S125-33. 85. Hoffmann, K., et al., Correlation of psychooncological distress- screening and quality of life assessment in neurosurgical patients. Oncotarget, 2017. 8(67): p. 111396-111404. 86. Goebel, S., M. von Harscher, and H.M. Mehdorn, Comorbid mental disorders and psychosocial distress in patients with brain tumours and their spouses in the early treatment phase. Support Care Cancer, 2011. 19(11): p. 1797-805. 87. Singer, S., et al., Psychiatric co-morbidity, distress, and use of psycho-social services in adult glioma patients-a prospective study. Acta Neurochir (Wien), 2018. 160(6): p. 1187-1194. 88. D'Angelo, C., et al., State and trait anxiety and depression in patients with primary brain tumors before and after surgery: 1-year longitudinal study. J Neurosurg, 2008. 108(2): p. 281-6. 89. Bunevicius, A., et al., Psychological distress symptoms' clusters in brain tumor patients: factor analysis of depression and anxiety scales. Psychooncology, 2013. 22(12): p. 2860-3. 90. Ley, A., et al., Psychooncological distress in low-grade glioma patients-a monocentric study. Acta Neurochir (Wien), 2021. 91. Mainio, A., et al., Gender difference in relation to depression and quality of life among patients with a primary brain tumor. Eur Psychiatry, 2006. 21(3): p. 194-9. 92. Armstrong, C.W., et al., Clinical predictors of infection of central venous catheters used for total parenteral nutrition. Infect Control Hosp Epidemiol, 1990. 11(2): p. 71-8. 93. Kessler, R.A., et al., Is Psychiatric Depression a Presenting Neurologic Sign of Meningioma? A Critical Review of the Literature with Causative Etiology. World Neurosurg, 2018. 112: p. 64-72. 94. Wagner, A., et al., The relevant psychological burden of having a benign brain tumor: a prospective study of patients undergoing surgical treatment of cranial meningiomas. J Neurosurg, 2019. 131(6): p. 1840-1847. 95. Bunevicius, A., et al., Screening for psychological distress in neurosurgical brain tumor patients using the Patient Health Questionnaire-2. Psychooncology, 2013. 22(8): p. 1895-900. 96. Renovanz, M., et al., Factors associated with supportive care needs in glioma patients in the neuro-oncological outpatient setting. J Neurooncol, 2017. 133(3): p. 653-662. 97. Rooney, A.G., et al., Screening for major depressive disorder in adults with glioma using the PHQ-9: a comparison of patient versus proxy reports. J Neurooncol, 2013. 113(1): p. 49-55. 98. Bunevicius, A., et al., Predictors of health-related quality of life in neurosurgical brain tumor patients: focus on patient-centered perspective. Acta Neurochir (Wien), 2014. 156(2): p. 367-74. 99. Renovanz, M., et al., Postsurgical screening for psychosocial disorders in neurooncological patients. Acta Neurochir (Wien), 2013. 155(12): p. 2255-61. 100. Keir, S.T., et al., Distress persists in long-term brain tumor survivors with glioblastoma multiforme. J Cancer Surviv, 2008. 2(4): p. 269-74. 101. Goebel, S., et al., Distress in patients with newly diagnosed brain tumours. Psychooncology, 2011. 20(6): p. 623-30. 102. Tomitaka, S., et al., Distribution of psychological distress is stable in recent decades and follows an exponential pattern in the US population. Sci Rep, 2019. 9(1): p. 11982. 103. Arnold, S.D., et al., Evaluation and characterization of generalized anxiety and depression in patients with primary brain tumors. Neuro Oncol, 2008. 10(2): p. 171-81. 104. Randazzo, D. and K.B. Peters, Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients. CNS Oncol, 2016. 5(4): p. 241-9. 105. Halkett, G.K., et al., Predictors of distress and poorer quality of life in High Grade Glioma patients. Patient Educ Couns, 2015. 98(4): p. 525-32. 106. Weitzner, M.A., C.A. Meyers, and K. Byrne, Psychosocial functioning and quality of life in patients with primary brain tumors. J Neurosurg, 1996. 84(1): p. 29-34. 107. Taphoorn, M.J., E.M. Sizoo, and A. Bottomley, Review on quality of life issues in patients with primary brain tumors. Oncologist, 2010. 15(6): p. 618-26. 108. Taphoorn, M.J., et al., Assessment of quality of life in patients treated for low-grade glioma: a preliminary report. J Neurol Neurosurg Psychiatry, 1992. 55(5): p. 372-6. 109. Fischbeck, S., et al., [Burden and need for psychosocial intervention of glioblastoma patients]. Psychother Psychosom Med Psychol, 2011. 61(12): p. 518-24. 110. Renovanz, M., et al., Evaluation of the psychological burden during the early disease trajectory in patients with intracranial tumors by the ultra-brief Patient Health Questionnaire for Depression and Anxiety (PHQ-4). Support Care Cancer, 2019. 27(12): p. 4469-4477. 111. Renovanz, M., et al., Screening for distress in patients with intracranial tumors during the first 6 months after diagnosis using self-reporting instruments and an expert rating scale (the basic documentation for psycho-oncology short form - PO-Bado SF). Oncotarget, 2018. 9(57): p. 31133-31145. 112. Dolbeault, S., et al., Screening for psychological distress in two French cancer centers: feasibility and performance of the adapted distress thermometer. Palliat Support Care, 2008. 6(2): p. 107-17. 113. Sun, H., et al., A Systematic Review and Meta-analysis of the Distress Thermometer for Screening Distress in Asian Patients with Cancer. J Clin Psychol Med Settings, 2020. 114. Bidstrup, P.E., et al., Accuracy of the Danish version of the 'distress thermometer'. Psychooncology, 2012. 21(4): p. 436-43. 115. Mitchell, A.J., Pooled results from 38 analyses of the accuracy of distress thermometer and other ultra-short methods of detecting cancer-related mood disorders. J Clin Oncol, 2007. 25(29): p. 4670-81. 116. Taphoorn, M.J. and M. Klein, Cognitive deficits in adult patients with brain tumours. Lancet Neurol, 2004. 3(3): p. 159-68. | |||||||
| Lizenz: |  Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz | |||||||
| Bezug: | Oktober 2013-Mai 2016 (Datenerfassung), Mai 2016-Januar 2024 (Datenerfassung, Veröffentlichung, Einreichen) | |||||||
| Fachbereich / Einrichtung: | Medizinische Fakultät » Institute » Institut für Neuropathologie | |||||||
| Dokument erstellt am: | 26.05.2025 | |||||||
| Dateien geändert am: | 26.05.2025 | |||||||
| Promotionsantrag am: | 28.01.2024 | |||||||
| Datum der Promotion: | 27.03.2025 |
